87 results on '"Genovese, M.C."'
Search Results
2. PE.Di-014 - Tolérance et efficacité à 5 ans d’abatacept sous-cutané chez des patients présentant une PR modérée à sévère et une réponse inadéquate au MTX : extension à long terme de l’étude de phase III, randomisée et en double aveugle ACQUIRE
3. Faible activité et rémission sous filgotinib [FIL] chez les patients PR ayant présenté une réponse inadéquate aux bDMARDs: analyse en sous-groupes de l’étude de phase 3 FINCH2
4. Profil de tolérance jusqu’à 8,4 ans de baricitinib dans le traitement de la polyarthrite rhumatoïde : mise à jour d’une analyse intégrée de la tolérance
5. Analyse intégrée de 7 essais cliniques sur la tolérance du filgotinib [FIL] dans le traitement de la polyarthrite rhumatoïde [PR]
6. TP3 THE CONSISTENCY OF US REAL-WORLD RHEUMATOID ARTHRITIS DISEASE-MODIFYING ANTIRHEUMATIC DRUG TREATMENT PATTERNS WITH AMERICAN COLLEGE OF RHEUMATOLOGY GUIDELINES
7. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
8. Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients
9. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
10. Golimumab, a human antibody to tumour necrosis factor (alpha) given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
11. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies
12. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2
13. PDG70 SHORT DURATION OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS) BEFORE AND AFTER BECOMING A CSDMARD INADEQUATE RESPONDER (IR) IN RHEUMATOID ARTHRITIS (RA) PATIENTS
14. Duration of Response in a Phase 3 Study of Sarilumab Plus Methotrexate in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis
15. ASSOCIATION BETWEEN CLINICAL AND RADIOGRAPHIC RESPONSES, AND PHYSICAL FUNCTION IN A PHASE 3 STUDY OF SARILUMAB PLUS METHOTREXATE IN PATIENTS WITH ACTIVE, MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS
16. EFFICACY AND SAFETY OF SARILUMAB IN SUBGROUPS OF PATIENTS WITH RHEUMATOID ARTHRITIS FROM 2 PHASE 3 STUDIES
17. FRI0077 Hepatitis b virus reactivation in patients with rheumatoid arthritis treated with baricitinib: post-hoc analysis from clinical trials
18. THU0101 Tissue metabolite of type i collagen, c1m, and crp predicts structural progression of rheumatoid arthritis
19. SAT0341 Efficacy and safety of ixekizumab in patients with active psoriatic arthritis and previous inadequate response to tnf inhibitors: 52-week results from a phase 3 study
20. Unlocking the 'PAD' lock on rheumatoid arthritis: perhaps a panel of antigens containing citrulline may explain RA: many questions remain
21. Tolérance et efficacité à 5 ans d’abatacept sous-cutané chez des patients présentant une PR modérée à sévère et une réponse inadéquate au MTX : extension à long terme de l’étude de phase III, randomisée et en double aveugle ACQUIRE
22. FRI0227 Five-Year Safety and Efficacy of Subcutaneous Abatacept in Patients with Moderate To Severely Active RA and An Inadequate Response To MTX: Long-Term Extension of The Phase III, Double-Blind, Randomized Acquire Study
23. SAT0160 Clinical and Radiographic Outcomes after 2 Years of Sarilumab in Patients with Rheumatoid Arthritis
24. SAT0149 Radiographic Outcomes in Patients Achieving Clinical Remission or Low Disease Activity in A Phase 3 Study of Sarilumab plus Methotrexate in Patients with Active, Moderate-To-Severe Rheumatoid Arthritis
25. FRI0228 Sarilumab Dose Reduction To Manage Laboratory Abnormalities in An Open-Label Extension Study in RA Patients
26. THU0138 Secondary Efficacy Results Up To Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimiar) with Adalimumab Reference Product in Patients with Moderate To Severe Rheumatoid Arthritis despite Methotrexate Therapy
27. SAT0058 Consistency of Radiographic Responses with Sarilumab plus Methotrexate across Subpopulations of Patients with Rheumatoid Arthritis in A Phase 3 Study
28. SAT0174 Efficacy of Sarilumab plus csDMARDs in Rheumatoid Arthritis Patients Who Had An Inadequate Response To One or More than One Prior TNF Inhibitor
29. THU0140 Efficacy and Safety Analysis by Overall anti-Drug Antibody Results Up To Week 30 in Patients with Rheumatoid Arthritis Treated with Sb2 (An Infliximab Biosimilar) or Infliximab Reference Product in Phase III Study
30. OP0223 Safety and Efficacy of ABT-494, A Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis with An Inadequate Response To Methotrexate
31. THU0146 Impact of anti-Drug Antibodies on Efficacy and Safety Up To Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimilar) with Adalimumab Reference Product in Patients with Moderate To Severe Rheumatoid Arthritis despite Methotrexate Therapy
32. Oskira-1: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Methotrexate
33. Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
34. Effect of golimumab combined with methotrexate on radiographic progression in rheumatoid arthritis: comment on the article by Emery et al Reply
35. Sarilumab for the Treatment of Moderate-to-Severe Rheumatoid Arthritis: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, International Study
36. Extracellular 14-3-3 eta: An Early Rheumatoid Arthritis Pathogenic Factor
37. SAFETY OF SUBSEQUENT BIOLOGIC THERAPY IN RA PATIENTS WHO DISCONTINUED RITUXIMAB
38. GOLIMUMAB AND RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS: RESULTS OF GO-BEFORE AND GO-FORWARD STUDIES
39. AB0321 Predicting the Need for Rescue Medication Using Baseline Variables: Evidence from Rheumatoid Arthritis (RA) Patients in the Sarilumab Mobility Phase 3 Trial
40. FRI0173 Efficacy of Sarilumab in Moderate and Severe Rheumatoid Arthritis as Defined by Baseline DAS28-CRP Scores: The Mobility Study
41. SAT0349 Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Tumor Necrosis Factor Inhibitors: Table 1
42. THU0175 Effects of Baricitinib on Multibiomarker Disease Activity Scores and Their Components in a Phase 2B Study in Moderate-to-Severe Rheumatoid Arthritis Patients: Table 1
43. FRI0058 Improvements in Health Related Quality of Life (HRQOL) Reported by Rheumatoid Arthritis (RA) Patients in a Randomized Controlled Trial [RCT] of Sarilumab [Mobility] that Met or Exceeded the Patient Acceptable Symptom State [Pass] And Normative Values
44. SAT0198 Effect of Increased Sarilumab Dose on Efficacy and Safety Outcomes in Poorly Responding Rheumatoid Arthritis (RA) Patients: The Mobility Study
45. OP0175 Two-Year Clinical Response to Brodalumab, An Anti-IL-17 Receptor Antibody, in Patients with Psoriatic Arthritis
46. OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study
47. SAT0185 Clinical and Radiographic Efficacy of Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naïve Patients with Rheumatoid Arthritis in a Phase 3, Randomized, Double-Blind, Placebo-Controlled International Study
48. AN ASSESSMENT OF THE SERIOUS INFECTION RATE IN RITUXIMAB-TREATED RHEUMATOID ARTHRITIS (RA) PATIENTS WHO SUBSEQUENTLY RECEIVED OTHER BIOLOGIC THERAPIES: A FOLLOW-UP FROM RITUXIMAB CLINICAL TRIALS
49. Automated, non-contrast MRI for detection of synovitis using diffusion-weighted dess
50. AB0752 Efficacy and Safety of Brodalumab over One Year in Patients with Psoriatic Arthritis with and without Prior Exposure to A Biologic
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.